RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.

scientific article published on 16 July 2009

RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1365-2141.2009.07812.X
P698PubMed publication ID19624538
P5875ResearchGate publication ID26688035

P50authorTorsten HaferlachQ66370751
Ulrike BacherQ66370775
Claudia HaferlachQ66370782
Susanne SchnittgerQ66370791
Tamara WeissQ95649714
Claudia TschulikQ114293330
P2093author name stringWolfgang Kern
P2860cites workUsefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapyQ35143841
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRQ58455808
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectleukemiaQ29496
P304page(s)665-668
P577publication date2009-07-16
P1433published inBritish Journal of HaematologyQ4970200
P1476titleRQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
P478volume146

Search more.